BRAF

Across TCGA pan-cancer cohorts, BRAF mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated BRAF data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher BRAF mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated BRAF expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

LSCC, PDAC, and GBM are the cancer types where BRAF mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	1.000	0.871	.003	20	view →
PDAC	DFS	Tertile	IV	0.749	0.217	.024	10	view →
GBM	OS	Quartile	All	0.931	0.820	.022	2	view →
HNSC	DFS	Quartile	II,III,IV	1.000	0.923	.037	1	view →
CCRCC	DFS	Median	II,III,IV	1.000	0.542	.036	1	view →
LUAD	OS	Median	II,III,IV	0.999	0.869	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

BRAF–LSCC (DFS)

Open the LSCC breakdown →